Effects of N-acetylcysteine on Pulmonary Functions in Patients with Systemic Sclerosis: A Randomized Double Blind, Placebo Controlled Study

Author(s): Samrad Mehrabi*, Maryam M. Moradi, Zohre Khodamoradi, Mohammad A. Nazarinia

Journal Name: Current Rheumatology Reviews

Volume 16 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Systemic sclerosis (SSc) is a systematic and rare autoimmune disease that affects many organs. N-acetylcysteine (NAC), thiol-containing compound, can act both as the precursor of reduced glutathione and direct scavenger of reactive oxygen species.

Objective: We assessed the clinical effect of NAC on the pulmonary function test of patients with diffuse scleroderma.

Methods: This study is a randomized double-blind clinical trial that was done on 25 patients with diffuse SSc without lung involvement on primary chest high-resolution computed tomography. Placebo was administered for 13 patients and 1200 milligram NAC for 12 patients. Body plethysmography parameters were assessed at the beginning of the study and after 24 weeks.

Results: Patients in the two groups were matched in the basic demographic data like age, duration of disease, and modified Rodnan skin score. The analysis showed no significant differences in parameters of plethysmography between the two groups. After importing the data of 2 patients in the placebo-treated group, who developed interstitial lung disease, DLCO in the placebo-treated group was 90.69 ± 21.29 milliliter at the end of the study, which significantly decreased compared with the beginning of the study (102.30 ± 13.83 ml). Also, changes of DLCO between the two groups were significantly different.

Conclusion: In this trial, the sensitivity of DLCO as the first marker in the evaluation of pulmonary function in patients with SSc was confirmed. On the other hand, NAC had no effect versus placebo in a period of 24 weeks.

Keywords: Systemic sclerosis, Scleroderma, interstitial lung disease, pulmonary function test, N-acetyl cysteine, clinical trial.

[1]
Correa MJU, Mariz HA, Andrade LEC, Kayser C. [Oral N-acetylcysteine in the treatment of Raynaud’s phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial]. Rev Bras Reumatol 2014; 54(6): 452-8.
[http://dx.doi.org/10.1016/j.rbr.2014.07.001] [PMID: 25458027]
[2]
van Laar JM, Farge D, Sont JK, et al. EBMT/EULAR Scleroderma Study Group.Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311(24): 2490-8.
[http://dx.doi.org/10.1001/jama.2014.6368] [PMID: 25058083]
[3]
Khanna D, Nagaraja V, Tseng CH, et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther 2015; 17(1): 372.
[http://dx.doi.org/10.1186/s13075-015-0872-2] [PMID: 26704522]
[4]
Herzog EL, Mathur A, Tager AM, Feghali-Bostwick C, Schneider F, Varga J. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct? Arthritis Rheumatol 2014; 66(8): 1967-78.
[http://dx.doi.org/10.1002/art.38702] [PMID: 24838199]
[5]
Desbois AC, Cacoub P. Systemic sclerosis: An update in 2016. Autoimmun Rev 2016; 15(5): 417-26.
[http://dx.doi.org/10.1016/j.autrev.2016.01.007] [PMID: 26802722]
[6]
Yousif M, Habib R, Esaely H, Yasin R, Sonbol A, Eds. Interleukin-6 in systemic sclerosis and potential correlation with pulmonary involvement.European Respiratory Journal. SHEFFIELD S10 2PX, ENGLAND: EUROPEAN RESPIRATORY SOC JOURNALS LTD 2014.
[7]
Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respiratory Soc 2013.
[http://dx.doi.org/10.1183/09059180.00005512]
[8]
Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database Annals of the rheumatic diseases 2010.http://dx.doi.org/annrheumdis114264
[9]
Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010; 24(3): 387-400.
[http://dx.doi.org/10.1016/j.berh.2009.12.002] [PMID: 20534372]
[10]
Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000; 43(11): 2437-44.
[http://dx.doi.org/10.1002/1529-0131(200011)43:11<2437:AID-ANR10>3.0.CO;2-U] [PMID: 11083266]
[11]
Fraticelli P, Gabrielli B, Pomponio G, et al. Imatinib in Scleroderma Italian Study Group.Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther 2014; 16(4): R144.
[http://dx.doi.org/10.1186/ar4606] [PMID: 25007944]
[12]
Joven BE, Almodovar R, Carmona L, Carreira PE, Eds. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital Seminars in arthritis and rheumatism. Elsevier 2010.
[13]
Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42(12): 2660-5.
[http://dx.doi.org/10.1002/1529-0131(199912)42:12<2660:AID-ANR23>3.0.CO;2-N] [PMID: 10616015]
[14]
Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177(11): 1248-54.
[http://dx.doi.org/10.1164/rccm.200706-877OC] [PMID: 18369202]
[15]
Tay T, Ferdowsi N, Baron M, Stevens W, Hudson M, Proudman SM, Eds. Measures of disease status in systemic sclerosis: A systematic review Seminars in arthritis and rheumatism. Elsevier 2017.
[16]
Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156(6): 1897-901.
[http://dx.doi.org/10.1164/ajrccm.156.6.9706065] [PMID: 9412572]
[17]
Radomska-Leśniewska DM, Skopińska-Rózewska E, Jankowska-Steifer E, et al. N-acetylcysteine inhibits IL-8 and MMP-9 release and ICAM-1 expression by bronchoalveolar cells from interstitial lung disease patients. Pharmacol Rep 2010; 62(1): 131-8.
[http://dx.doi.org/10.1016/S1734-1140(10)70250-4] [PMID: 20360623]
[18]
Gillissen A. [Anti-inflammatory efficacy of N-acetylcysteine and therapeutic usefulness]. Pneumologie 2011; 65(9): 549-57.
[http://dx.doi.org/10.1055/s-0030-1256592] [PMID: 21761386]
[19]
Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Idiopathic Pulmonary Fibrosis Clinical Research Network.Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366(21): 1968-77.
[http://dx.doi.org/10.1056/NEJMoa1113354] [PMID: 22607134]
[20]
Sakamoto S, Muramatsu Y, Satoh K, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology 2015; 20(3): 445-52.
[http://dx.doi.org/10.1111/resp.12477] [PMID: 25639750]
[21]
van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65(11): 2737-47.
[http://dx.doi.org/10.1002/art.38098] [PMID: 24122180]
[22]
Assayag D, Kaduri S, Hudson M, Hirsch A, Baron M. High resolution computed tomography scoring systems for evaluating interstitial lung disease in systemic sclerosis patients. Rheumatology: Current Research 2012.
[http://dx.doi.org/10.4172/2161-1149.S1-003]
[23]
Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis 1979; 38(4): 356-61.
[http://dx.doi.org/10.1136/ard.38.4.356] [PMID: 386962]
[24]
Demedts M, Behr J, Buhl R, et al. IFIGENIA Study Group.High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353(21): 2229-42.
[http://dx.doi.org/10.1056/NEJMoa042976] [PMID: 16306520]
[25]
Bando M, Hosono T, Mato N, et al. Long-term efficacy of inhaled N-acetylcysteine in patients with idiopathic pulmonary fibrosis. Intern Med 2010; 49(21): 2289-96.
[http://dx.doi.org/10.2169/internalmedicine.49.4011] [PMID: 21048362]
[26]
Wagner PD, Mathieu-Costello O, Bebout DE, Gray AT, Natterson PD, Glennow C. Protection against pulmonary O2 toxicity by N-acetylcysteine. Eur Respir J 1989; 2(2): 116-26.
[PMID: 2703040]
[27]
Wolters PJ. Could N-acetylcysteine slow progression of idiopathic pulmonary fibrosis by inhibiting EMT?. Am Physiological Soc 2009.
[http://dx.doi.org/10.1152/ajplung.00283.200]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 2
Year: 2020
Page: [149 - 157]
Pages: 9
DOI: 10.2174/1573397115666191212092608
Price: $65

Article Metrics

PDF: 18
HTML: 1